The active ingredient in Saxenda and Victoza -- one of the first GLP-1 drugs for weight loss. Not as strong as semaglutide, but it has years of clinical data behind it and a well-established safety profile. Requires daily injections since it doesn't last as long in your body.
Dosing
Start at 0.6 mg per day and gradually increase to 3.0 mg per day over several weeks. Daily injection required (shorter-lasting than semaglutide).
Benefit Profile
Medical Considerations
Contraindications
- ✕Personal or family history of medullary thyroid carcinoma
- ✕MEN2 syndrome
- ✕Pregnancy/nursing
- ✕History of pancreatitis
Drug Interactions
Recommended Monitoring
- →HbA1c every 3 months
- →Renal function
- →Lipase/amylase if symptoms
- →Heart rate
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Pricing
| Vendor | Variant | Price | |
|---|---|---|---|
| Peptide Sciences ✕ Announced voluntary shutdown | 3mg | $79.00BEST |
Published Research
Liraglutide monotherapy and add on therapy on obese women with polycystic ovarian syndromes: a systematic review and meta-analysis.
Liraglutide pharmacokinetics and exposure-response in adolescents with obesity.
A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass.
Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder.
Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial.
Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial.
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.
Metabolic resilience: liraglutide's potential in alleviating depressive symptoms.